IDEAYA Biosciences, Inc.
NASDAQ:IDYABiotechnology
Healthcare
$26.17 -1.45%
-$0.45 today
- Market cap
- $2.53B
- Beta
- -0.05
- P/E (TTM)
- -19.5
- EPS (TTM)
- -$1.58
52W Low $20.50High $39.28
Volume 1.42M
Average 1.44M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$71.10M
FY 2025 · Annual
Investing Cash Flow
$69.98M
FY 2025 · Annual
Financing Cash Flow
$29.78M
FY 2025 · Annual
-95.6% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (49.76M) | (58.66M) | (112.96M) | (274.48M) | (113.7M) |
| Depreciation & Amortization | 1.73M | 2.1M | 4.01M | 3.83M | 4.59M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.24M | 11.63M | 18.49M | 34.75M | 46.12M |
| Change in Working Capital | (17.81M) | (41.56M) | (13.21M) | 11.55M | 1.87M |
| Accounts Receivables | 774K | 892K | 193K | 15K | 0 |
| Inventory | 3.79M | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.17M | 1.86M | 2.64M | 8.28M | 2.7M |
| Other Working Capital | (23.54M) | (44.31M) | (16.04M) | 3.25M | (829K) |
| Other Non-Cash Items | 1.83M | (695K) | (11.55M) | (23.23M) | (9.98M) |
| Operating Cash Flow | (55.78M) | (87.18M) | (115.22M) | (247.58M) | (71.1M) |
| Capital Expenditures | (2.64M) | (3.44M) | (2.37M) | (3.86M) | (2.37M) |
| Acquisitions (Net) | 67.02M | 33.4M | 0 | 0 | 0 |
| Purchases of Investments | (315M) | (255.81M) | (595.98M) | (1.19B) | (607.89M) |
| Sales of Investments | 247.97M | 225.85M | 439.89M | 692.61M | 680.23M |
| Other Investing Activities | (67.02M) | (33.4M) | 0 | 0 | 0 |
| Investing Cash Flow | (69.67M) | (33.4M) | (158.46M) | (502.56M) | 69.98M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 143.25M | 94.96M | 309.76M | 654.23M | 29.78M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.2M | 2.2M | 10.77M | 13.92M | 0 |
| Financing Cash Flow | 145.45M | 97.17M | 362.72M | 677.55M | 29.78M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (210K) |
| Net Change in Cash | 20.01M | (23.41M) | 89.04M | (72.59M) | 28.45M |
| Free Cash Flow | (58.42M) | (90.62M) | (117.59M) | (251.44M) | (73.47M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$113.7M
+ D&A$4.6M
+ Stock-Based Comp$46.1M
+ Deferred Tax$0
+ Working Capital$1.9M
- Other Non-Cash-$10.0M
= Operating Cash Flow-$71.1M
- Capex-$2.4M
= Free Cash Flow-$73.5M
Analysis
FY2025 free cash flow is -$73.5M. FCF conversion is 64.6% of net income. Operating cash flow was -$71.1M, with capex of -$2.4M. The largest bridge item is Stock-Based Comp at $46.1M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-8 | S-8 filing | Nov 3, 2026 | |
| 8-K | Current report | Nov 3, 2026 | |
| 10-Q | Quarterly report | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 8, 2026 | |
| SC 13G | SC 13G filing | Aug 14, 2026 |
Does IDYA generate free cash flow?
IDEAYA Biosciences, Inc. (IDYA) generated -$73.47M of free cash flow in fiscal 2025.
How much operating cash flow does IDYA produce?
Operating cash flow was -$71.10M, before capital expenditures of $2.37M.
Continue the stock analysis
Jump to another research area for this company.